The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.c

Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

Publications

Sasaki H, Miyata J, Maki Y, Kimizuka Y, Hayashi N, Fujikura Y, Kawana A

Development of Allergic Bronchopulmonary Aspergillosis in a Patient with Crohn's Disease.

Internal medicine (Tokyo, Japan). 2019;58(19):2835-2838

Van Sanford C, Obeidat AZ, Hagen M, Zabeti A

A case of fatal invasive aspergillosis in a patient with neurosarcoidosis treated with infliximab.

The International journal of neuroscience. 2019;129(6):619-622

Judson MA

Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance.

Chest. 2009;135(5):1358-1359

De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE

Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?

Infection control and hospital epidemiology. 2003;24(7):477-82